Source disclosure: February 13, 2026
RaQualia Pharma Inc. [4579.T]
TOKYO, Feb 13 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) outlined its business plan through December 2028, projecting stable growth and continuous profitability.
The company expects operating profits to reach ¥910 million in fiscal 2028, up from the black ink achieved in fiscal 2025. Key products such as Teogoprazan are expanding globally, currently sold in 19 countries and targeting further globalization. In Korea, K-CAB® sales remain robust, reaching approximately ¥217.9 billion in fiscal 2025. The patent victory ensures exclusive sales until 2031, with potential additional revenue from expanded indications.
RaQualia also highlighted strategic partnerships, particularly with HK inno.N, which has secured significant funding to bolster its financial foundation and develop high-value pipelines. The company plans to create three development candidates by December 2028, focusing on programs like glucagon receptor agonists and IRAK-M degraders. Financially, RaQualia projects cumulative revenues of ¥3,980 for fiscal 2026, with ongoing contributions from milestone payments and royalties. The firm anticipates continued growth driven by Teogoprazan's expansion and subsidiary Fiamex’s business performance.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing